Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EBP11-F5 · EBP11

Peptide · developed by Entera Bio

Phase 1 Most advanced trial (none active)
ENTX Developer
1 Registered trials

What is EBP11-F5?

EBP11-F5 is a peptide corresponding to the first 34 amino acids of human parathyroid hormone, hPTH(1-34). It is studied in hypoparathyroidism, osteoporosis and bone fractures.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
EBP11, hPTH(1-34)
Drug type
Peptide
Therapy area
Endocrine, Musculoskeletal
Developer
Entera Bio Ltd. (ENTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05965167 Phase 1 Hypoparathyroidism Completed ENTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fractures, BoneHypoparathyroidismOsteoporosisOther Disease

More from Entera Bio

Follow ENTX, the company behind EBP11-F5

See ENTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ENTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.